Glycosorb®-ABO was used for the first time in England in connection with a blood group incompatible heart transplantation. The patient, a 10 year old boy, blood group O, who weighed 10 kg, was treated with Glycosorb®-ABO. After a number of days the boy began to produce blood group-specific antibodies...
Recently published studies show that results of blood group incompatible kidney transplants, in which patients were treated with the Glycorex Transplantation AB’s product, Glycosorb®-ABO, are excellent even over longer follow-up periods and are equivalent to results obtained from blood group...
Glycorex Transplantation AB has received product approval for the Glycosorb®-ABO A/B column. This approval means that the Glycosorb®-ABO A/B column now can be used clinically in the EU. Treatment with the product Glycosorb®-ABO has been shown to be effective and provides excellent clinical...
A kidney transplantation offers better quality of life than dialysis for patients with severe renal failure, as dialysis means less freedom for the patient and high costs for society. Shortage of organs limits the number of transplantations, especially as it has previously been almost impossible to...
“I was prepared for 100 treatments if needed!” The first transplantation across blood groups with Glycorex Transplantation’s technology was done at the Surgery Department of Transplantation, Karolinska University Hospital Huddinge, outside Stockholm Sweden, in October 2001. The female patient...
Canada, comments:
St. Michael’s first in North America to use blood-cleaning procedure for kidney transplant, allowing man to receive kidney from brother with different blood type
Man to Receive Kidney from Brother With Different Blood Type: Novel Blood-Cleaning Procedure Used for Kidney Transplant
India, comments:
The India’s first ever ABO – Incompatible (Non-matching blood groups) Kidney Transplantation performed Using the
read more..
(From published articles in clinical journals)
Highly Specific for anti-A/B antibodies:
Minimal influence on other plasma components and minimum of other complications.
Thus, more patient plasma volumes can be treated per session and if necessary more sessions can be performed
Also patients with high titers can be treated to low titers, 1:4 or lower
Specific treatment:
Minimal bleeding, infections and other
read more..